$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

$alny Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000117867022000016 Filed on April 28, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$213.3M	$177.6M
YoY Change	20.1%	78.5%
Cost Of Revenue	$23.46M	$23.02M
YoY Change	1.89%	73.08%
Gross Profit	$189.8M	$154.5M
YoY Change	22.82%	79.34%
Gross Profit Margin	89.0%	87.03%
Selling, General & Admin	$154.5M	$146.9M
YoY Change	5.18%	15.86%
% of Gross Profit	81.39%	95.03%
Research & Development	$169.9M	$185.9M
YoY Change	-8.61%	9.63%
% of Gross Profit	89.51%	120.29%
Depreciation & Amortization	$9.460M	$12.60M
YoY Change	-24.92%	65.79%
% of Gross Profit	4.98%	8.15%
Operating Expenses	$324.4M	$332.8M
YoY Change	-2.52%	12.29%
Operating Profit	-$146.7M	-$186.3M
YoY Change	-21.22%	-11.37%
Interest Expense	$42.36M	$32.52M
YoY Change	30.28%
% of Operating Profit
Other Income/Expense, Net	-$92.62M	-$13.02M
YoY Change	611.34%	-145.67%
Pretax Income	-$239.4M	-$199.3M
YoY Change	20.11%	9.71%
Income Tax	$985.0K	$1.016M
% Of Pretax Income
Net Earnings	-$240.3M	-$200.3M
YoY Change	20.0%	9.92%
Net Earnings / Revenue	-112.7%	-112.8%
Basic Earnings Per Share	-$2.00	-$1.71
Diluted Earnings Per Share	-$2.00	-$1.71
COMMON SHARES
Basic Shares Outstanding	120.4M shares	117.1M shares
Diluted Shares Outstanding	120.4M shares	117.1M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.208B	$1.653B
YoY Change	33.58%	26.72%
Cash & Equivalents	$534.1M	$379.5M
Short-Term Investments	$1.673B	$1.273B
Other Short-Term Assets	$115.1M	$76.00M
YoY Change	51.4%	-23.0%
Inventory	$78.52M	$73.94M
Prepaid Expenses
Receivables	$156.5M	$110.6M
Other Receivables	$23.42M	$519.1M
Total Short-Term Assets	$2.590B	$2.470B
YoY Change	4.84%	55.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$504.4M	$464.6M
YoY Change	8.57%	8.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$69.82M	$42.68M
YoY Change	63.61%	124.23%
Total Long-Term Assets	$843.9M	$785.2M
YoY Change	7.47%	13.0%
TOTAL ASSETS
Total Short-Term Assets	$2.590B	$2.470B
Total Long-Term Assets	$843.9M	$785.2M
Total Assets	$3.434B	$3.255B
YoY Change	5.48%	42.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$54.92M	$45.38M
YoY Change	21.01%	12.1%
Accrued Expenses	$355.9M	$280.5M
YoY Change	26.88%	53.11%
Deferred Revenue	$131.8M	$116.3M
YoY Change	13.32%	35.21%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$606.0M	$494.8M
YoY Change	22.46%	46.06%
LONG-TERM LIABILITIES
Long-Term Debt	$676.7M	$191.6M
YoY Change	253.19%
Other Long-Term Liabilities	$120.8M	$60.46M
YoY Change	99.84%	557.33%
Total Long-Term Liabilities	$120.8M	$60.46M
YoY Change	99.84%	557.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$606.0M	$494.8M
Total Long-Term Liabilities	$120.8M	$60.46M
Total Liabilities	$3.032B	$2.329B
YoY Change	30.2%	150.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.679B	-$4.786B
YoY Change	18.66%	22.42%
Common Stock	$6.118B	$5.749B
YoY Change	6.42%	8.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$401.2M	$926.2M
YoY Change
Total Liabilities & Shareholders Equity	$3.434B	$3.255B
YoY Change	5.48%	42.8%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$240.3M	-$200.3M
YoY Change	20.0%	9.92%
Depreciation, Depletion And Amortization	$9.460M	$12.60M
YoY Change	-24.92%	65.79%
Cash From Operating Activities	-$171.2M	-$235.7M
YoY Change	-27.36%	-4.27%
INVESTING ACTIVITIES
Capital Expenditures	$17.86M	$17.18M
YoY Change	3.96%	-12.43%
Acquisitions
YoY Change
Other Investing Activities	$75.00K	$4.198M
YoY Change	-98.21%
Cash From Investing Activities	-$147.4M	$71.35M
YoY Change	-306.61%	-37.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$34.96M	$51.18M
YoY Change	-31.7%	-5.0%
NET CHANGE
Cash From Operating Activities	-$171.2M	-$235.7M
Cash From Investing Activities	-$147.4M	$71.35M
Cash From Financing Activities	$34.96M	$51.18M
Net Change In Cash	-$285.9M	-$117.0M
YoY Change	144.27%	47.71%
FREE CASH FLOW
Cash From Operating Activities	-$171.2M	-$235.7M
Capital Expenditures	$17.86M	$17.18M
Free Cash Flow	-$189.1M	-$252.8M
YoY Change	-25.23%	-4.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001178670
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-36407
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	ALNYLAM PHARMACEUTICALS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0602661
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 West Kendall Street,
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Henri A. Termeer Square
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2022Q1	dei	City Area Code CityAreaCode	617
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	551-8200
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	ALNY
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	120813559	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	534081000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	819975000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1673485000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1548617000	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	31997000	USD
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	66972000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	156533000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	198571000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	78516000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	86363000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	115065000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	88078000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	2589677000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2808576000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	504389000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	501958000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	228769000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	231675000	USD
CY2022Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	40889000	USD
CY2021Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	40891000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	69821000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60204000	USD
CY2022Q1	us-gaap	Assets Assets	3433545000	USD
CY2021Q4	us-gaap	Assets Assets	3643304000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	54916000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	73426000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	355936000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	395174000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	41290000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	40548000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	131838000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	149483000	USD
CY2022Q1	alny	Royalty Liability Current RoyaltyLiabilityCurrent	21983000	USD
CY2021Q4	alny	Royalty Liability Current RoyaltyLiabilityCurrent	37079000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	605963000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	695710000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	277388000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	281347000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	157668000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	152360000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	676710000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	675697000	USD
CY2022Q1	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1193822000	USD
CY2021Q4	alny	Royalty Liability Noncurrent RoyaltyLiabilityNoncurrent	1151024000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	120828000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	98963000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	3032379000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	3055101000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	120729000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120729000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120182000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	120182000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	1207000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1202000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	6116558000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	6058453000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38065000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33259000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5678534000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5438193000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	401166000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	588203000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3433545000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3643304000	USD
CY2022Q1	us-gaap	Revenues Revenues	213259000	USD
CY2021Q1	us-gaap	Revenues Revenues	177566000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23457000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23023000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-92624000	USD
CY2022Q1	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	12170000	USD
CY2021Q1	alny	Cost Of Collaboration Manufacturing And Royalties CostOfCollaborationManufacturingAndRoyalties	8039000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	169893000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	185899000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	154471000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	146859000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	359991000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	363820000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-146732000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-186254000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	42362000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	32515000	USD
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1012000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	450000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-51274000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19044000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13021000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-239356000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-199275000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	985000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1016000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-240341000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-200291000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.00
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.00
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	120393000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	120393000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117080000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117080000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-240341000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	29852000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-200291000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7217000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2376000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	6848000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-35000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-58000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4806000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6905000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-245147000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-193386000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	588203000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28059000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30051000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4806000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-240341000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	401166000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1016247000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	47034000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56295000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6905000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-200291000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	926190000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-240341000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-200291000	USD
CY2022Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	9460000	USD
CY2021Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	12601000	USD
CY2022Q1	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	10318000	USD
CY2021Q1	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	10261000	USD
CY2022Q1	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	27702000	USD
CY2021Q1	alny	Non Cash Interest Expense On Sale Of Future Royalties NonCashInterestExpenseOnSaleOfFutureRoyalties	28184000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	29293000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	55690000	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-31161000	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	47016000	USD
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	21177000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	30777000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-39696000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10709000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1926000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1934000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13654000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-48736000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-66573000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-12325000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-27804000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	10672000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	9060000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-171193000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-235660000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17859000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17178000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	634705000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	345954000	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	505220000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	438682000	USD
CY2022Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	9400000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-117041000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	822153000	USD
CY2021Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	10650000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	9400000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	10650000	USD
CY2022Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	75000	USD
CY2021Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	4198000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-147419000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	71352000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	27123000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	46977000	USD
CY2022Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	7833000	USD
CY2021Q1	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	4200000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34956000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51177000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2238000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3910000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-285894000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8318000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7289000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	499046000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	536259000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	382005000	USD
CY2022Q1	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top five biotech company by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, delivering exceptional financial performance and driving profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2022, we have four products that have received marketing approval, including one partnered product, and five late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from three commercialized products, ONPATTRO, GIVLAARI and OXLUMO, primarily in the U.S., Europe and Japan.</span></div>
CY2022Q1	alny	Number Of Marketed Products NumberOfMarketedProducts	4	product
CY2022Q1	alny	Number Of Partnered Products NumberOfPartneredProducts	1	product
CY2022Q1	alny	Number Of Clinical Programs In Late Stages NumberOfClinicalProgramsInLateStages	5	program
CY2022Q1	alny	Number Of Commercialized Products NumberOfCommercializedProducts	3	product
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and variants thereof, and the actions taken to contain or treat it or vaccinate against it, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2022Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	23421000	USD
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	73266000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	78683000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	88627000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9500000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	25300000	USD
CY2022Q1	alny	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	-3900000	USD
CY2021Q1	alny	Increase Decrease In Research And Development Expense IncreaseDecreaseInResearchAndDevelopmentExpense	-5400000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1736298000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8869000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1727451000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1605245000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1639000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1603615000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1673485000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1548617000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	53966000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	54998000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1727451000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1603615000	USD
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	20372000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	14754000	USD
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	91262000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	100942000	USD
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10428000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7005000	USD
CY2022Q1	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	122062000	USD
CY2021Q4	alny	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	122701000	USD
CY2022Q1	alny	Capitalized Inventory CapitalizedInventory	7000000	USD
CY2021Q4	alny	Capitalized Inventory CapitalizedInventory	7100000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	534081000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	379543000	USD
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	2178000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	2462000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	536259000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	382005000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	2377000	USD
CY2022Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	7183000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4806000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	6847000	USD
CY2021Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-58000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6905000	USD
CY2022Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.14
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29293000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55690000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14703000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15397000	shares

Files In Submission

Name	View Source	Status
0001178670-22-000016-index-headers.html	Edgar Link	pending
0001178670-22-000016-index.html	Edgar Link	pending
0001178670-22-000016.txt	Edgar Link	pending
0001178670-22-000016-xbrl.zip	Edgar Link	pending
alny-20220331.htm	Edgar Link	pending
alny-20220331.xsd	Edgar Link	pending
alny-20220331_cal.xml	Edgar Link	unprocessable
alny-20220331_def.xml	Edgar Link	unprocessable
alny-20220331_g1.jpg	Edgar Link	pending
alny-20220331_htm.xml	Edgar Link	completed
alny-20220331_lab.xml	Edgar Link	unprocessable
alny-20220331_pre.xml	Edgar Link	unprocessable
alny2022q110-qex101.htm	Edgar Link	pending
alny2022q110-qex311.htm	Edgar Link	pending
alny2022q110-qex312.htm	Edgar Link	pending
alny2022q110-qex321.htm	Edgar Link	pending
alny2022q110-qex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2022 Q1 Form 10-Q Financial Statement

#000117867022000016 Filed on April 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2022 Q1 Form 10-Q Financial Statement

#000117867022000016 Filed on April 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny